Italian Network MDS Registry
NCT02808858 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000
Last updated 2025-03-04
Summary
Epidemiological data collection of adult patients affected by myelodysplastic syndrome (MDS) newly diagnosed.
Conditions
- Myelodysplastic-Myeloproliferative Diseases
Sponsors & Collaborators
-
Fondazione Italiana Sindromi Mielodisplastiche-ETS
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 106 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-09-30
- Primary Completion
- 2016-06-30
- Completion
- 2032-05-31
Countries
- Italy
Study Locations
More Related Trials
-
An European Platform for Translational Research in Myelodysplastic Syndromes
NCT04174547 ·Status: UNKNOWN
-
Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms
NCT04460950 ·Status: RECRUITING
-
Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes
NCT03058588 ·Status: RECRUITING
-
Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
NCT04587856 ·Status: RECRUITING ·Phase: NA
-
Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70
NCT05367583 ·Status: UNKNOWN
-
GENOMED4ALL: Improving MDS Classification and Prognosis by AI
NCT04889729 ·Status: UNKNOWN
-
Characterization of the Mechanisms of Resistance to Azacitidine
NCT01210274 ·Status: RECRUITING
-
Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine
NCT02489929 ·Status: UNKNOWN ·Phase: NA
-
Clinical and Genomic Registry of MDS in Asia
NCT03169296 ·Status: UNKNOWN
-
Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN
NCT05817955 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
NCT02323139 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome
NCT06764511 ·Status: RECRUITING
-
Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes
NCT03621241 ·Status: RECRUITING
-
Biocollection in MyeloDysplastic Syndrome (P-MDS)
NCT04869683 ·Status: RECRUITING ·Phase: NA
-
Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT01362140 ·Status: COMPLETED ·Phase: PHASE3
-
Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS
NCT04801563 ·Status: UNKNOWN ·Phase: NA
-
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes
NCT02619565 ·Status: COMPLETED ·Phase: NA
-
Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia
NCT02986620 ·Status: COMPLETED
-
5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)
NCT00897130 ·Status: COMPLETED ·Phase: PHASE2
-
Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples
NCT04251078 ·Status: RECRUITING
-
Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients
NCT04806906 ·Status: COMPLETED ·Phase: PHASE2
-
Collection of Samples From Patients With MDS
NCT03072498 ·Status: UNKNOWN
-
Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome
NCT00977132 ·Status: TERMINATED ·Phase: PHASE2
-
Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT
NCT02872662 ·Status: COMPLETED
-
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
NCT01048034 ·Status: COMPLETED ·Phase: PHASE2